Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study.

Eltawil KM, Berry R, Abdolell M, Molinari M.

HPB (Oxford). 2012 May;14(5):341-50. doi: 10.1111/j.1477-2574.2012.00455.x.

2.

Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre.

Eltawil KM, Berry R, Abdolell M, Molinari M.

HPB (Oxford). 2012 Mar;14(3):162-70. doi: 10.1111/j.1477-2574.2011.00420.x. Epub 2012 Jan 9.

3.

Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.

Li T, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L, Tang ZY, Fan J.

Liver Int. 2014 Jul;34(6):953-60. doi: 10.1111/liv.12364. Epub 2013 Nov 20.

PMID:
24134199
4.

Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.

Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH, Lee DY, Han KH, Chon CY, Park JY.

BMC Cancer. 2013 Jan 3;13:5. doi: 10.1186/1471-2407-13-5.

5.

Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.

Zhang DZ, Wei XD, Wang XP.

World J Gastroenterol. 2015 Apr 21;21(15):4635-43. doi: 10.3748/wjg.v21.i15.4635.

6.

Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.

Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, Zhou Y, Fan J.

Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.

PMID:
22451237
7.

Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.

Li HL, Ji WB, Zhao R, Duan WD, Chen YW, Wang XQ, Yu Q, Luo Y, Dong JH.

World J Gastroenterol. 2015 Mar 28;21(12):3599-606. doi: 10.3748/wjg.v21.i12.3599.

8.

Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: propensity score analysis.

Jiang JH, Guo Z, Lu HF, Wang XB, Yang HJ, Yang FQ, Bao SY, Zhong JH, Li LQ, Yang RR, Xiang BD.

World J Gastroenterol. 2015 Apr 21;21(15):4627-34. doi: 10.3748/wjg.v21.i15.4627.

9.

Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus.

Ye JZ, Zhang YQ, Ye HH, Bai T, Ma L, Xiang BD, Li LQ.

World J Gastroenterol. 2014 Dec 7;20(45):17141-7. doi: 10.3748/wjg.v20.i45.17141.

10.

Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.

Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R.

Eur J Gastroenterol Hepatol. 2012 Apr;24(4):437-43. doi: 10.1097/MEG.0b013e3283502241.

PMID:
22261548
11.

Efficacy of hepatic resection vs transarterial chemoembolization for solitary huge hepatocellular carcinoma.

Zhu SL, Zhong JH, Ke Y, Ma L, You XM, Li LQ.

World J Gastroenterol. 2015 Aug 28;21(32):9630-7. doi: 10.3748/wjg.v21.i32.9630.

12.

Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.

Agarwal A, Yadav AK, Kumar A, Gupta S, Panwala HK, Redhu N, Hariprasad S, Ranjan P, Arora A, Gupta A.

Indian J Gastroenterol. 2015 Mar;34(2):117-26. doi: 10.1007/s12664-015-0544-9. Epub 2015 May 5.

PMID:
25937484
13.

Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.

Koh PS, Chan AC, Cheung TT, Chok KS, Dai WC, Poon RT, Lo CM.

HPB (Oxford). 2016 Jan;18(1):72-8. doi: 10.1016/j.hpb.2015.07.005.

14.

Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.

Wang Y, Chen Y, Ge N, Zhang L, Xie X, Zhang J, Chen R, Wang Y, Zhang B, Xia J, Gan Y, Ren Z, Ye S.

Ann Surg Oncol. 2012 Oct;19(11):3540-6. doi: 10.1245/s10434-012-2368-5. Epub 2012 Apr 25.

PMID:
22532305
15.

Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.

Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, Xu LF.

World J Gastroenterol. 2014 Dec 14;20(46):17483-90. doi: 10.3748/wjg.v20.i46.17483.

16.

Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.

Song MJ, Bae SH, Lee JS, Lee SW, Song do S, You CR, Choi JY, Yoon SK.

Korean J Intern Med. 2016 Mar;31(2):242-52. doi: 10.3904/kjim.2015.112. Epub 2016 Feb 15.

17.

Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.

Garwood ER, Fidelman N, Hoch SE, Kerlan RK Jr, Yao FY.

Liver Transpl. 2013 Feb;19(2):164-73. doi: 10.1002/lt.23552. Epub 2012 Dec 12.

18.

Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre.

Molinari M, Kachura JR, Dixon E, Rajan DK, Hayeems EB, Asch MR, Benjamin MS, Sherman M, Gallinger S, Burnett B, Feld R, Chen E, Greig PD, Grant DR, Knox JJ.

Clin Oncol (R Coll Radiol). 2006 Nov;18(9):684-92.

PMID:
17100154
19.

Clinicopathologic Characteristics of Hepatocellular Carcinoma With Reactive Ductule-like Components, a Subset of Liver Cancer Currently Classified as Combined Hepatocellular-Cholangiocarcinoma With Stem-Cell Features, Typical Subtype.

Shibahara J, Hayashi A, Misumi K, Sakamoto Y, Arita J, Hasegawa K, Kokudo N, Fukayama M.

Am J Surg Pathol. 2016 May;40(5):608-16. doi: 10.1097/PAS.0000000000000579.

PMID:
26735856

Supplemental Content

Support Center